

# Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases

Katja Goricar, Viljem Kovac, Metoda Dodic-Fikfak, Vita Dolzan, Alenka Franko

doi: 10.2478/raon-2020-0011

**SUPPLEMENTARY TABLE S1.** Unadjusted odds for asbestos-related diseases in subjects with different MSLN rs1057147 genotypes

Genotype	Any asbestos-related disease vs. No disease		Pleural plaques vs. No disease		Asbestosis vs. No disease		MM vs. No disease		MM vs. Pleural plaques	
	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
GG	reference		reference		reference		reference		reference	
GA	1.23 (0.71–2.13)	0.458	1.19 (0.68–2.09)	0.544	1.14 (0.61–2.15)	0.687	1.45 (0.78–2.70)	0.246	1.21 (0.82–1.80)	0.331
AA	0.81 (0.33–2.00)	0.645	0.57 (0.22–1.50)	0.252	1.22 (0.44–3.38)	0.701	1.10 (0.39–3.10)	0.862	1.93 (0.92–4.06)	0.082
GA+AA	1.14 (0.68–1.89)	0.620	1.05 (0.62–1.78)	0.849	1.16 (0.65–2.08)	0.625	1.37 (0.77–2.44)	0.289	1.30 (0.90–1.89)	0.167

CI = confidence interval; MM = malignant mesothelioma; OR = odds ratio

**SUPPLEMENTARY TABLE S2.** The probability of survival in malignant mesothelioma patients with different MSLN rs1057147 genotypes

Genotype	PFS			OS		
	Median (25%–75%), months	HR (95% CI)	p	Median (25%–75%), months	HR (95% CI)	p
GG	9.3 (5.2–16.1)	reference		22.2 (9.9–50.8)	reference	
GA	7.3 (5.7–11.2)	1.39 (0.96–2.01)	0.084	14.0 (8.7–22.7)	1.68 (1.11–2.54)	0.015
AA	7.0 (5.3–13.1)	1.40 (0.74–2.66)	0.306	16.0 (11.3–18.1)	1.91 (0.96–3.81)	0.066
GA+AA	7.1 (5.6–11.2)	1.39 (0.98–1.98)	0.068	15.1 (8.7–22.2)	1.72 (1.15–2.55)	0.008

CI = confidence interval; HR = hazard ratio; OS = overall survival; PFS = progression-free survival